⌑ I · The MechanismHow it actually works.
Rapamycin binds the intracellular protein FKBP12, and the resulting complex inhibits mTORC1 (mechanistic Target Of Rapamycin Complex 1), a master regulator of cellular growth, protein synthesis, and metabolism. mTORC1 integrates signals from nutrients (especially amino acids), growth factors, and cellular energy status to determine whether the cell should engage in growth and proliferation or in maintenance and recycling.[1]
Inhibition of mTORC1 produces a cellular state that resembles caloric restriction at the molecular level: reduced protein synthesis, increased autophagy (the cellular recycling process that removes damaged proteins and organelles), enhanced mitochondrial quality control, and reduced senescent cell burden. These are the molecular hallmarks the geroscience field has identified as drivers of age-related decline.[1][2]
At higher doses or with chronic administration, rapamycin also inhibits mTORC2, which produces several side effects — glucose intolerance, lipid abnormalities, and immune suppression — that are dose-related and reversible with proper protocol design.[1]
The longevity hypothesis depends on intermittent dosing — pulsing the system rather than continuously suppressing it. Daily high-dose rapamycin (transplant dose) produces well-documented metabolic and immune side effects. Once-weekly off-label dosing is theorized to capture the benefits of mTOR pulsing while permitting recovery between doses.
⌑ II · The EvidenceWhat the research actually shows.
- Mouse lifespan (the headline result). Harrison et al. (2009, Nature) and the NIH Interventions Testing Program demonstrated that rapamycin extended median lifespan in mice by 9-14% in males and 14-25% in females, even when treatment began in late life (600 days, equivalent to ~60 human years). The result has been independently replicated across multiple strains and laboratories — among the most robust single findings in geroscience.[3]
- Healthspan markers (mice). Beyond raw lifespan, mice on rapamycin show improvements in cardiac function, cognitive performance, muscle quality, and immune function in advanced age.[4]
- Immune function (humans). Mannick et al. (2014, Sci Transl Med) demonstrated that 6 weeks of RTB101 (an mTOR inhibitor related to rapamycin) in elderly subjects improved response to influenza vaccination by 20%, reversing some aspects of immunosenescence. A subsequent RCT in 1,024 subjects showed reduced respiratory tract infection incidence.[5]
- Periodontitis (humans). An et al. (2020) found 8 weeks of rapamycin improved periodontal disease markers in a small clinical trial — relevant because periodontitis is increasingly understood as a marker of immune aging.[6]
- PEARL trial (just-reported human longevity RCT). The first dedicated rapamycin-for-longevity RCT in healthy older adults reported in 2024. Results showed safety of 5-10 mg/week intermittent dosing over 48 weeks, with secondary endpoints suggesting improvements in lean mass and pain. Insufficient to claim lifespan extension but supports safety of the off-label protocol.[7]
- Transplant population data. Long-term registry data on transplant recipients (who take much higher chronic doses) shows reduced cancer incidence compared to other immunosuppressants — a possible signal for the longevity hypothesis but confounded by patient selection.[1]
⌑ III · The Off-Label Longevity ProtocolHow it is actually used.
Rapamycin (sirolimus) is FDA-approved for the prevention of organ rejection in transplant patients at higher daily doses. Off-label longevity use is a separate practice with a different dosing strategy. This protocol describes what is reported in the longevity medicine literature; it is not medical advice.
Common reported dose
5-8 mg orally once weekly, sometimes split into two doses 12 hours apart. Some practitioners titrate from 2 mg/week upward to assess tolerability.[2]
Timing
Some protocols recommend dosing in a fasted state to maximize absorption (rapamycin bioavailability is ~15% with food, ~30% fasted). Others recommend with a fatty meal to slow absorption. No consensus.
Monitoring
Off-label longevity practitioners typically monitor: fasting glucose, HbA1c, lipid panel, complete blood count (watching for cytopenias), liver enzymes, lipid panel, mTOR-mediated trough levels (rarely required at weekly dosing). Baseline labs and follow-up at 3-6 months minimum.
Duration
Indefinite is the implicit assumption, but human data on long-term off-label use is limited to ~5-7 years of accumulated patient experience.
Sourcing
Prescription rapamycin is dispensed through licensed pharmacies. Compounded formulations exist. Direct-purchase from research chemical suppliers is illegal and the products are unverified for purity and dose.
⌑ IV · Side Effects & ConsiderationsWhat to watch for.
- Mouth ulcers (stomatitis). The most common dose-limiting effect in chronic transplant use, less common at intermittent off-label dosing. Manage with dose reduction.[1]
- Lipid abnormalities. Hypertriglyceridemia and elevated LDL are common in chronic high-dose use; less pronounced with intermittent dosing. Monitor at baseline and follow-up.[1]
- Glucose intolerance / insulin resistance. Dose-related effect on glucose homeostasis. Intermittent dosing minimizes risk. Pre-existing diabetes is a relative contraindication.[1]
- Immune suppression. Real at chronic high doses (transplant indication). At weekly off-label doses, effect is much smaller but not zero. Consider live vaccine timing.[5]
- Wound healing. mTOR inhibition modestly slows wound healing. Surgeons may request discontinuation around elective procedures.[1]
- Drug interactions. Rapamycin is metabolized via CYP3A4 and is a P-glycoprotein substrate. Interactions with grapefruit, ketoconazole, erythromycin, calcium channel blockers, and many others are significant and clinically important.[1]
⌑ V · Codex VerdictThe state of the evidence.
Rapamycin is the longevity intervention with the strongest animal evidence in geroscience. The mouse data is remarkable in its consistency and replicability. The human off-label movement is largely driven by people extrapolating from that animal data, supported by emerging human safety data and small clinical endpoints (immune, periodontal, body composition).
What we do NOT have: a human RCT showing rapamycin extends human lifespan or healthspan beyond what existing geriatric care provides. The first dedicated longevity RCTs (PEARL, others) are just now reporting. The earliest off-label users have ~10 years of accumulated experience without major adverse signals at intermittent doses.
For the right candidate (older adult, well-monitored, with realistic expectations), the risk-benefit may be acceptable. For the casual biohacker chasing TikTok longevity trends, this is a powerful immunosuppressant being used outside its approved indication. The Codex documents what is known. The medical decision belongs with a qualified physician.